| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price |
|---|---|---|---|---|---|---|---|---|
| CD39 | HOT CD9-M52H3 | Mouse CD39 / ENTPD2 Protein, His Tag (active enzyme, MALS verified) | Mouse | HEK293 | ![]() | MALSSDS-PAGE | $130.00 20ug | |
| CD39 | HOTAvitag CD9-H82E5 | Biotinylated Human CD39 / ENTPD1 Protein, His,Avitag™ (active enzyme) | Human | HEK293 | ![]() | SDS-PAGE | $380.00 25ug | |
| CD39 | HOT CD9-H52H4 | Human CD39 / ENTPD1 Protein, His Tag (active enzyme, MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $435.00 100ug | |
| CD39 | Cynomolgus CD39 Protein, His Tag (active enzyme, MALS verified) | Cynomolgus | CHO | ![]() | MALSSDS-PAGE | $130.00 20ug | ||
| CD39 | Human CD39 Protein, Mouse IgG2a Fc Tag (active enzyme) | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug | ||
| CD39 | Human CD39 / ENTPD1 (Q96A, N99A, E143A, R147E) Protein, His Tag (active enzyme, MALS verified) | Human | HEK293 | ![]() | MALSSDS-PAGE | $410.00 100ug | ||
| CD39 | Human CD39 (R138A, M139A, E142K) Protein, His Tag (active enzyme) | Human | HEK293 | ![]() | SDS-PAGE | $410.00 100ug | ||
| CD39 | Avitag CD9-H82E8 | Biotinylated Human CD39 (R138A, M139A, E142K) Protein, His,Avitag™ (active enzyme) | Human | HEK293 | ![]() | SDS-PAGE | $360.00 25ug |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| TTX-030 | TTX-030 | Phase 2 Clinical | Adimab LLC | Lymphoma; Pancreatic Neoplasms; Solid tumours | Details |
| IPH-5201 | IPH-5201 | Phase 2 Clinical | Inserm, Orega Biotech | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Solid tumours | Details |
| JS-019 | JS-019 | Phase 2 Clinical | Beijing Enrini Biotechnology Co Ltd | Eosinophilia; Lymphoma; Solid tumours | Details |
| ES-014 | ES-014 | Phase 2 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Neoplasms; Solid tumours | Details |
| Perenostobart | SRF-617 | Phase 1 Clinical | Surface Oncology Inc | Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours | Details |
| HB-0046 | HB0046; HB-0046 | Phase 1 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours | Details |
| PUR-001 | PUR-001 | Phase 1 Clinical | Purinomia Biotech Inc | Solid tumours | Details |
| AB-598 | AB598 | Phase 1 Clinical | Arcus Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Neoplasms; Neoplasms; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | Details |
| AGX-148 | AGX-148; AGX148 | Phase 1 Clinical | AgonOx Inc | Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Urogenital Neoplasms | Details |
| Eurestobart | ES-002023 | Phase 1 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Solid tumours | Details |
| ES-002 | ES-002 | Phase 1 Clinical | Elpiscience (Shanghai) Biopharma Ltd | Neoplasms; Solid tumours | Details |